Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.59 – $1.71
Volume12,223
Market cap$3M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for PPBT.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for PPBT.
Recent news
Company coverage with links to the original publishers.
Purple Biotech will present new preclinical data on its CAPTN-3 platform of conditionally activated tri-specific antibodies at the ESMO Immuno-Oncology 2025 Congress, showcasing potential advances in cancer treatment targeting tumor immune evasion and drug resistance.
Purple Biotech received a Nasdaq letter indicating non-compliance with minimum bid price requirements, with 180 days to regain compliance by raising its stock price above $1.00 per share.
Purple Biotech closed a public offering raising $6 million upfront, with potential additional proceeds of $12 million through short-term warrant exercises. The company plans to use funds for oncology therapeutic candidate development and working capital.
Purple Biotech reported significant progress in its oncology pipeline, including promising Phase 2 results for CM24 in pancreatic cancer, advancements in the CAPTN-3 tri-specific antibody platform, and initiation of a Phase 2 study for NT219 in head and neck cancer.
Purple Biotech is advancing its novel agent NT219 into a Phase 2 study in combination with pembrolizumab or cetuximab for the treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The study aims to address the significant unmet medical need in this patient population.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.